The role of angiotensinconverting enzyme and angiotensin II receptors of the second type in the pathogenesis of proliferative diseases of the prostate


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Angiotensin converting enzyme, angiotensin II, angiotensin II receptors of the first and second types represent the “classical” axis of regulation of the renin-angiotensin system. Objective: to analyze the role of the components of the renin-angiotensin system in the pathogenesis of proliferative lesions of the prostate glan Materials and methods. The study included 63 patients who underwent transrectal prostate biopsy. The first group consisted of 19 patients with benign prostatic hyperplasia, the second group consisted of 19 men whose prostate cancer was detected during repeated biopsy, the third group consisted of 25 men with prostate cancer detected during primary prostate biopsy. The expression of angiotensin II type II (AT2-R) receptors in prostate tissue was evaluated using primary polyclonal antibodies Angiotensin II Type 2 Receptor and the EnVision FLEX imaging system (Dako, Denmark) according to a standard technique. The activity of angiotensin converting enzyme (ACE) was determined in the secret of the prostate gland, Results. It was found that the activity of ACE in the secret of the prostate gland in proliferative diseases is significantly higher than in the “healthy” prostate. The highest activity of ACE was noted for benign prostatic hyperplasia, and the minimum - for prostate cancer. The expression of AT2-R in prostate tissues in proliferative diseases of the prostate gland has its own characteristics. The expression of AT2-R in the prostate stroma turned out to be the same, in the nuclei of epithelial cells, the level of expression of AT2-R decreased in the range of BPH-PIN-CP. Thus, an increase in the activity of ACE, the accumulation of angiotensin II in prostate secretions in proliferative prostate diseases against the background of a deficiency of AT2-R is the metabolic basis of malignant transformation of the prostate gland. Conclusion. The levels of ACE activity in prostate secretion and the expression of AT2-R in prostate tissue during primary prostate biopsy can be considered as promising prognostic tools for early detection of prostate malignancy.

Full Text

Restricted Access

About the authors

M. B Chibichyan

Federal State Budgetary Educational Institution of Higher Education “Rostov State Medical University” of the Ministry of Health of the Russian Federation

Email: michel_dept@mail.ru
Dr.Med.Sci., Associate Professor of the Department of Urology and Human Reproductive Health with the course of pediatric urology and andrology at the Faculty of Medicine and Pedagogy Rostov-on-Don, Russia

E. A Chernogubova

Federal State Budgetary Instituton of science “Federal Research Center Southern Scientific Center of the Russian Academy of Sciences”

Email: eachernogubova@mail.ru
Ph.D. senior researcher head Laboratory of Experimental Biology Rostov-on-Don, Russia

A. V Avetyan

Federal State Budgetary Educational Institution of Higher Education “Rostov State Medical University” of the Ministry of Health of the Russian Federation

Email: arsenalfvo@yandex.ru
Postgraduate student of the Department of Urology and Human Reproductive Health (with the course of pediatric urology and andrology) Rostov-on-Don, Russia

T. O Lapteva

Federal State Budgetary Educational Institution “National Medical Research Center of Oncology” of the Ministry of Health of the Russian Federation “

Email: lto-96@yandex.ru
pathologist of the highest category, head of the pathological department Rostov-on-Don, Russia

I. A Pavlenko

State budgetary institution of the Rostov region “Anatomical Pathology Bureau”

Email: foxxtrot@mail.ru
Biologist of the Department of High-Tech Diagnostic Methods of the State Budgetary !nstitution Rostov-on-Don, Russia

M. I Kogan

Federal State Budgetary Educational Institution of Higher Education “Rostov State Medical University” of the Ministry of Health of the Russian Federation; Federal State Budgetary Instituton of science “Federal Research Center Southern Scientific Center of the Russian Academy of Sciences”

Email: dept_kogan@mail.ru
Dr.Med.Sci, Professor, Head of the Department of Urology and Human Reproductive Health (with the course of pediatric urology-andrology); Chief Researcher Laboratory of Experimental Biology Rostov-on-Don, Russia; Rostov-on-Don, Russia

References

  1. Phua T.J. The Etiology and Pathophysiology Genesis of Benign Prostatic Hyperplasia and Prostate Cancer: A New Perspective. Medicines. 2021,8:30. doi: 10.3390/medicines8060030
  2. Урология. Национальное руководство под ред. Н.А. Лопаткина. М.: ГЭОТАР-Медиа, 2009.
  3. Аляев Ю.Г. Болезни предстательной железы. М.: ГЭОТАР-Медиа, 2015.
  4. Lee Ch.L. Kuo H.Ch. Pathophysiology of benign prostate enlargement and lower urinary tract symptoms: Current concepts.Tzu Chi Medical Journal 2017;29(2):79-83. doi: 10.4103/tcmj.tcmj_20_17
  5. Cho A., Chughtai B., Te A.E. Benign Prostatic Hyperplasia and Male Lower Urinary Tract Symptoms: Epidemiology and Risk Factors. Curr Bladder Dysfunct Rep. 2020;15:60-65. doi: 10.1007/s11884-019-00566-z
  6. Brawer M.K. Prostatic intraepithelial neoplasia: an overview. Rev Urol. 2005;7 (Suppl 3):S11-S18.
  7. Юрмазов З.А. Место ПИН в опухолевой патологии предстательной железы. Сибирский онкологический журнал. 2009;S1:224-225.
  8. Billis A., Magna L.A. !nflammatory atrophy of the prostate. Prevalence and significance. Arch. Pathol. Lab. Med. 2003;127(7):840-844. doi: 10.5858/2003-127-840-LAOTP.
  9. Trabzonlu L., Kulac I., Zheng Q., Hicks J.L., Haffner M.C., Nelson W.G., Sfanos K.S., Ertunc O. Lotan T.L., Heaphy C.M., Meeker A.K., Yegnasubramanian S., De Marzo A.M. Molecular Pathology of High-Grade Prostatic Intraepithelial Neoplasia: Challenges and Opportunities. Cold Spring Harb Perspect Med. 2019;9(4):a030403. doi: 10.1101/cshperspect.a030403.
  10. Чибичян М.Б., Коган М.И., Лаптева Т.О., Белоусов И.И., Иванов А.Г., Черногубова Е.А. Перипростатическое воспаление как фактор риска развития стеноза везико-уретрального анастомоза после радикальной простатэктомии. Урология. 2015;6:52-57.
  11. Karakiewicz P.І., Benayoun S., Begin L.R. Duclos A., Valiquette L., McCormack M., Benard F., Saad F., Perrotte P. Chronic inflammation is negatively associated with prostate cancer and high-grade prostatic intraepithelial neoplasia on needle biopsy. ІМ J Clin Pract. 2007;61(3):425- 430. doi: 10.1111/j.1742-1241.2006.00905.x.
  12. de Bono J.S., Guo C., Gurel B., De Marzo A.M., Sfanos K.S., Mani R.S., Gil J., Drake C.G., Alimonti A. Prostate carcinogenesis: inflammatory storms. Nat Rev Cancer. 2020;20(8):455-469. doi: 10.1038/s41568-020-0267-9.
  13. Черногубова Е.А., Коган М.И. Ренин-ангиотензиновая система: роль в развитии и прогрессировании рака предстательной железы. Онкоурология. 2020; 16(4):181-190. doi: 10.17650/1726-9776-2020-16-4-181-190
  14. Santos R.A.S., Oudit G.Y., Verano-Braga T., Canta G., Steckelings U.M., Bader M. The renin-angiotensin system: going beyond the classical paradigms. Am J Physiol Heart Circ Physiol. 2019;316(5):H958-H970. doi: 10.1152/ajpheart.00723.2018.
  15. Кугаевская Е.В., Тимошенко О.С., Соловьева Н.И. Ангиотензин превращающий фермент: антигенные свойства доменов, роль в метаболизме пептида бета-амилоида и опухолевой прогрессии. Биомедицинская химия. 2015;61(3):301-311. doi: 10.18097/PBMC20156103301.
  16. Afsar B., Afsar R.E., Ertuglu L.A., Kuwabara M., Ortiz A., Covic A., Kanbay M. Renin-angiotensin system and cancer: epidemiology, cell signaling, genetics and epigenetics. Clin Transl. Oncol. 2021;23:682-696. doi: 10.1007/s12094-020-02488-3
  17. ГОСТ Р 52379-2005 Национальный стандарт РФ «Надлежащая клиническая практика» (Good Clinical Practice; GCP), утвержден приказом Федерального агентства по техническомурегулированию и метрологии от 27.09.2005. № 232-ст.
  18. Голиков П.П., Николаева Н.Ю. Экспресс-метод определения активности ангиотензинпревращающего фермента в сыворотке крови. Клиническая лабораторная диагностика 1998;(1):11-13.
  19. Dabbs D.J. Diagnostic Immunohistochemistry. 2nd edit. Philadelphia, Churchill Livingstone: Elsevier, 2006; 828 p.
  20. Реброва О.Ю. Статистический анализ медицинских данных. Применение пакета прикладных программ STATISTICA. М.: Медиа Сфера; 2002.
  21. Kryukova O.V., Tikhomirova V.E., Golukhova E.Z., Evdokimov V.V., Kalantarov G.F., Trakht I.N., Schwartz D.E., Dull R.O., Gusakov A.V., Uporov I.V., Kost O.A., Danilov S.M. Tissue Specificity of Human Angiotensin I-Converting Enzyme. PLoS One. 2015;10(11):e0143455. doi: 10.1371/journal.pone.0143455.
  22. Danilov S.M., Kadrev A.V., Kurilova O.V., Tikhomirova V.E., Kryukova O.V., Mamedov V.N., Kamalov D.M., Danilova N.V., Okhobotov D.A., Gayfullin N.M., Evdokimov V.V., Alekseev B.J., Kost O.A., Samokhodskaya L.M., Kamalov A.A. Tissue ACE phenotyping in prostate cancer. Oncotarget. 2019;10(59):6349-6361. doi: 10.18632/oncotarget.27276.
  23. Benigni A., Cassis P., Remuzzi G. Angiotensin II revisited: new roles in inflammation, immunology and aging. EMBO Mol Med. 2010;2(7):247- 257. doi: 10.1002/emmm.201000080.
  24. Горбунова Е.Н., Давыдова Д.А., Крупин В.Н. Хроническое воспаление и фиброз как факторы риска простатических интраэпителиальных неоплазий и рака предстательной железы. Соврем технол мед. 2011;(1):79-83.
  25. Cai T., Santi R., Tamanini I., Galli I.C., Perletti G., Bjerklund Johansen T.E., Nesi G. Current Knowledge of the Potential Links between Inflammation and Prostate Cancer.Int J Mol Sci. 2019;20(15):3833. doi: 10.3390/ijms20153833.
  26. Singh K.D., Karnik S. Angiotensin Receptors: Structure, Function, Signaling and Clinical Applications. J Cell Signal 2016;1(2):111. doi: 10.4172/jcs.1000111
  27. Kaschin E., Unger T. Angiotensin AT1/AT2 Receptors: Regulation, Signalling and Function. Blood Press. 2003; 12(2):70-88. doi: 10.1080/08037050310001057 21.
  28. AbdAlla S., Lother H., Abdel-tawab A.M., Quitterer U. The angiotensin II AT2 receptor is an AT1 receptor antagonist. J Biol Chem. 2001;276(43):39721- 39726. doi: 10.1074/jbc.M105253200.
  29. Dinh D.T., Frauman A.G., Somers G.R., Ohishi M., Zhou J., Casley D.J., Johnston C.I., Fabiani M.E. Evidence for activation of the renin-angiotensin system in the human prostate: increased angiotensin II and reduced AT(1) receptor expression in benign prostatic hyperplasia. J Pathol. 2002;196(2):213-219. doi: 10.1002/path.1021.
  30. Hunyady L., Catt K.J. Pleiotropic AT1 Receptor Signaling Pathways Mediating Physiological and Pathogenic Actions of Angiotensin II. Molecular Endocrinology. 2006;20:953-970. doi: 10.1210/me.2004-0536.
  31. Imai N., Hashimoto T., Kihara M., Yoshida S. Kawana I., Yazawa T., Kitamura H., Umemura S. Roles for host and tumor angiotensin II type 1 receptor in tumor growth and tumor-associated angiogenesis. Lab Invest. 2007;87(2):189-198. doi: 10.1038/labinvest.3700504.
  32. Septiadi I., Sugandiet S., Noegroho B.S., Tjahdjodjati, SafriadiF., Siregar S., Ricky A., Adi K., Sihombing A.T., Pramod S.V., Nasution R., Hernowo B. S. Angiotensin ii type-1 receptor (at1r) distribution in bph, high grade pin and adenocarcinoma of the prostate. Indonesian Journal of Urology. 2010;17(2): doi: 10.32421/juri.v17i2.348/
  33. Rodrigues-Ferreira S., Abdelkarim M., Dillenburg-Pilla P., Luissint A.C, di-Tommaso A., Deshayes F., Pontes C.L., Molina A., Cagnard N., Letourneur F., Morel M., Reis R.I., Casarini D.E., Terris B., Couraud P.O., Costa-Neto C.M., Di Benedetto M., Nahmias C. Angiotensin II Facilitates Breast Cancer Cell Migration and Metastasis. PLoS One. 2012;7(4):e35667. doi: 10.1371/journal.pone.0035667

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies